Diligence memo · auto-generated · as of July 2, 2026
Synthetic Biologics, Inc.
Synthetic Biologics, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Synthetic Biologics, Inc. operates in Biotechnology, based in ROCKVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Synthetic Biologics, Inc. has raised $48M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $13M on 2025-10-17.
Most recent recorded round closed around 2025-10-17.
Valuation (modeled)modeled
Provath models Synthetic Biologics, Inc. at approximately $37M (range $14M–$59M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.36× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 31 months.
Last raise 8 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 4.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 81% of Biotechnology peers (4293 compared).
Modeled value ranks above 39% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.